Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision from the French Ministry of Health and Social Affairs to reimburse interferon gamma release assays, or IGRAs, for latent TB screening in at risk patient populations.
Upon implementation of the new reimbursement codes, which is expected in the next 21 days, the French Ministry of Health and Social Affairs will provide reimbursement for the T-SPOT.TB test at a rate of approximately 60 Euros per test.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Also obtained through the acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure. The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company's fourth intended product line focused on the transplantation market. In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
CONTACTS:
For Media and Investor Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
[email protected]
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
[email protected]
